Exposure of CLL cells to TLR9 agonists and IL-2 further enhances cAMP release in response to CGS21680, confirming that in activated CLLs the adenosinergic axis is boosted [2]. The gene discussed is TLR9; the disease is B-cell chronic lymphocytic leukemia.